Institut Bordet - Retour à la page d'accueil

Denis Larsimont

Department : Anatomopathology
 
denis.larsimont [at] bordet.be

Publications

FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.

Authors : De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2019
Journal : EBioMedicine

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.

Authors : Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, Tkint de Roodenbeke D, Willard-Gallo K
Year : 2019
Journal : Cancer Lett

ESR1 mutations in metastatic lobular breast cancer patients.

Authors : Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, OLeary B, Van den Eynden G, Salgado R, Turner NC, Piccart-Gebhart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C
Year : 2019
Journal : NPJ Breast Cancer

Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.

Authors : Nguyen B, Veys I, Leduc S, Bareche Y, Majjaj S, Brown DN, Boeckx B, Sotiriou C, Larsimont D, Desmedt C
Year : 2019
Journal : J Natl Cancer Inst

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.

Authors : Bonnefoi H, Macgrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron D
Year : 2019
Journal : Br J Cancer

More publications »

Follow us!

Youtube

Exclusive images of the new Jules Bordet Institute!

Watch the video and discover the major project for the new Jules Bordet Institute. Magnificent images of the construction work on the   80,000 m² dedicated exclusively to cancer are accompanied by explanations on how the project was conceived to combine excellence of patient care with optimal well-being for patients and care staff.

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more